Management of Incessant Atrial Tachycardia in Infants

Incessant atrial tachycardia is an uncommon but potentially dangerous arrhythmia in infancy. It may begin antenatally or shortly after birth and continue for weeks or months, producing sustained tachycardia without the usual abrupt onset and termination of reentrant supraventricular tachycardia. A small atrial focus can drive the atria at a rate sufficient to exhaust ventricular reserve, leading to feeding difficulty, respiratory distress or heart failure.

The term describes a persistent clinical course rather than one specific mechanism. Automatic atrial tachycardia, macroreentrant atrial tachycardia and postoperative atrial arrhythmias may all require prolonged treatment. Management depends on the infant’s condition, ventricular function, associated heart disease and response to medication, while recognising that atrial tachycardia in a baby can deteriorate much faster than the same rhythm in an older child.

Evidence comes mainly from case reports and small paediatric series because randomised trials would be impractical in such a rare population. Multidisciplinary assessment by paediatric cardiologists, electrophysiology specialists, pharmacists and nurses is therefore central to choosing a safe, sustained strategy.

Recognising the rhythm early

Infants with atrial tachycardia may look uncomfortable, breathe rapidly, sweat during feeds or fail to gain weight. Some remain surprisingly well during the early phase, while others develop tachycardia-induced cardiomyopathy, cardiogenic shock or signs of low cardiac output. A neonate may present with poor feeding and lethargy, whereas an older infant can have irritability and reduced exercise tolerance. Fever, pain and hypovolaemia can increase the atrial rate and obscure the underlying rhythm.

A 12-lead electrocardiogram is essential and should be repeated while the tachycardia persists. Typical findings include an abnormal P-wave axis, P waves marching through the QRS complexes, variable atrioventricular conduction or complete atrioventricular dissociation. The QRS complex is usually narrow unless there is aberrancy or pre-existing ventricular disease. Continuous telemetry can establish the atrial rate and reveal whether short runs are becoming sustained.

Several rhythms must be distinguished, including sinus tachycardia, atrioventricular reentrant tachycardia, junctional ectopic tachycardia and atrial flutter. Adenosine may transiently block atrioventricular nodal conduction and expose independent P waves, but it usually does not terminate an automatic atrial tachycardia. Synchronised cardioversion is also often ineffective for an automatic focus, although it remains part of the resuscitation response for an unstable patient with a rhythm that may be reentrant.

Confirming the diagnosis and underlying cause

The assessment should combine rhythm documentation with an echocardiogram to determine ventricular function, chamber size and structural abnormalities. Electrolytes, magnesium, renal function, thyroid function and markers of infection or inflammation help identify reversible contributors. Clinicians should also review medication exposure, recent cardiac surgery, congenital heart disease and any family history of arrhythmia or sudden cardiac death.

Atrial tachycardia may follow surgery for congenital heart disease, occur with myocarditis or cardiomyopathy, or arise from an idiopathic ectopic focus. It can also be promoted by fever, catecholamine release, dehydration, anaemia or electrolyte imbalance. The distinction matters because removing an inciting factor may reduce the arrhythmia, while structural disease influences drug selection and the likelihood of recurrence.

Current evidence and practical reviews can be located through the journal’s clinical collections, which gather material on paediatric rhythms, mapping and device-based treatment. Treatment goals should be stated explicitly: control the ventricular rate, preserve ventricular function, minimise drug toxicity and, where possible, eliminate the arrhythmia without compromising future growth or conduction.

Pharmacological treatment

Initial management addresses haemodynamic stability and reversible triggers. Oxygen should be given for hypoxaemia rather than routinely, and intravenous access should be obtained when the infant is unstable. Fever, pain, dehydration and electrolyte abnormalities require prompt treatment. An experienced paediatric team should interpret the rhythm while supporting feeds, fluid balance and infection management, because cardioversion or escalating antiarrhythmic therapy will not reliably suppress an automatic focus if the underlying stimulus remains.

Beta-blockers such as esmolol or propranolol are commonly used to reduce the atrial and ventricular rate, with the choice influenced by respiratory status, cardiac function and the need for rapid titration. Intravenous amiodarone is another option when rapid control is required or beta-blockade is unsuitable. Amiodarone can be effective in postoperative atrial arrhythmias, but long-term use requires surveillance for thyroid dysfunction, hepatic toxicity, pulmonary effects and other adverse reactions.

Sotalol may be considered under specialist supervision after correction of electrolyte abnormalities and assessment of the QT interval, renal function and cardiac function. Magnesium is useful when magnesium deficiency contributes to the arrhythmia. Digoxin has a limited role because it may slow conduction without suppressing an automatic atrial focus, while verapamil is generally avoided in infants without highly experienced supervision because severe hypotension and collapse can occur. Flecainide or propafenone may be used in selected drug-resistant cases after structural heart disease has been assessed and with monitoring of the QRS duration, renal function and conduction.

In Australia, paediatric antiarrhythmic prescribing also requires attention to the Therapeutic Goods Administration, Pharmaceutical Benefits Scheme availability, hospital medicines governance and paediatric pharmacy advice. Infants may receive medicines outside their approved age indication, but the rationale, consent process, dosing and monitoring should be documented. Concentrations should be measured when appropriate, and each treatment trial needs predefined clinical and electrocardiographic endpoints so that ineffective therapy is not continued indefinitely.

Considering catheter ablation

Ablation is usually considered when arrhythmia remains uncontrolled despite carefully selected medication, particularly when ventricular function is deteriorating. Other indications include recurrent haemodynamic compromise, escalating drug toxicity or persistent tachycardia that prevents adequate feeding and growth. The decision should involve a paediatric electrophysiology team experienced in very small patients rather than treating the infant as a scaled-down adult.

Radiofrequency ablation and cryoablation are both used in selected infants. Electroanatomical mapping helps localise the earliest activation or a reentrant circuit, while intracardiac recordings and pacing manoeuvres establish the mechanism. The procedure is technically demanding because of small vessels, limited working space, movement and close relationship to the coronary arteries and atrioventricular conduction system. Vascular injury, perforation, collateral damage, atrioventricular block and recurrence are recognised risks.

Advanced mapping methods are evolving rapidly. Although developed largely for other arrhythmias, the journal’s discussion of mapping atrial fibrillation drivers illustrates how improved spatial resolution may reveal targets that are not visible on conventional recordings. These findings should not be applied directly to neonatal atrial tachycardia without paediatric evidence, but they point toward procedures that may reduce fluoroscopy and improve target identification. Ablation remains a centre-dependent option with reported success in selected infants, not a routine first-line treatment.

Coordinating care across Australia

Complex paediatric electrophysiology is concentrated in major children’s hospitals, including the Royal Children’s Hospital in Melbourne, Sydney Children’s Hospital at Randwick, Queensland Children’s Hospital in Brisbane and Perth Children’s Hospital. These tertiary services support referral networks, shared protocols and complex procedures. Families outside metropolitan areas may need interstate transfer, paediatric transport and coordinated outpatient follow-up, making telehealth useful for reviewing rhythm strips and medication plans.

Australia’s public and private systems shape access to treatment. A specialist referral usually remains necessary for definitive paediatric electrophysiology assessment, while Medicare rebates and Pharmaceutical Benefits Scheme subsidies influence outpatient consultation and prescription costs. Admission to a public hospital can provide access to inpatient investigations and medicines without relying on the same outpatient subsidy arrangements. Local general practitioners and paediatricians often coordinate with the tertiary centre, while emergency departments initiate transfer when an infant is unstable.

Practical communication is as important as technical detail. Australian families may describe a breathless baby as “not settling” or “off their feeds”, making a clear account of feeding, sleep, breathing and weight gain valuable. Aboriginal and Torres Strait Islander children from regional and remote communities may require additional support through Flying Health, patient travel schemes, interpreters and culturally safe care. These needs should be incorporated into the treatment plan from the outset.

Reporting detailed cases can improve the limited evidence base. Teams that document the rhythm mechanism, medicine exposure, imaging, ablation findings and long-term follow-up can review the journal’s author information before preparing a submission. Recognise persistent atrial tachycardia in a symptomatic infant, obtain paediatric electrophysiology advice early, and give families one coordinated plan for treatment, transfer and follow-up. Timely action protects ventricular function and makes a rare but treatable arrhythmia manageable.